Industry's perspective on challenges assessing the in vivo impact of removing titanium dioxide (TiO 2 ) from drug products.

MLA

Abend, Andreas, et al. “Industry’s Perspective on Challenges Assessing the in Vivo Impact of Removing Titanium Dioxide (TiO 2 ) from Drug Products.” Journal of Pharmaceutical Sciences, vol. 113, no. 11, Nov. 2024, pp. 3119–22. EBSCOhost, https://doi.org/10.1016/j.xphs.2024.08.002.

APA

Abend, A., Sperger, D., Diaz, D. A., Guo, R., Reul, R., & Wu, S.-J. (2024). Industry’s perspective on challenges assessing the in vivo impact of removing titanium dioxide (TiO 2 ) from drug products. Journal of Pharmaceutical Sciences, 113(11), 3119–3122. https://doi.org/10.1016/j.xphs.2024.08.002

Chicago

Abend, Andreas, Diana Sperger, Dorys Argelia Diaz, Ruiqiong Guo, Regina Reul, and Sy-Juen Wu. 2024. “Industry’s Perspective on Challenges Assessing the in Vivo Impact of Removing Titanium Dioxide (TiO 2 ) from Drug Products.” Journal of Pharmaceutical Sciences 113 (11): 3119–22. doi:10.1016/j.xphs.2024.08.002.